Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2013-01-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00112853
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma
- Conditions
- Retinoblastoma
- Interventions
- Biological: filgrastimDrug: CarboplatinDrug: CyclosporineDrug: EtoposideDrug: vincristine sulfateProcedure: cryosurgeryProcedure: laser therapy
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 71
- Registration Number
- NCT00110110
- Locations
- 🇨🇱
Hospital San Juan de Dios, Santiago, Chile
🇨🇦Children's and Women's Hospital of British Columbia, Vancouver, British Columbia, Canada
🇮🇳Sankara Nethralaya Super Specialty Clinic, Chennai, India
S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 34
- Registration Number
- NCT00109928
- Locations
- 🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸Sparrow Regional Cancer Center, Lansing, Michigan, United States
🇺🇸Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
- Conditions
- CancerLeukemiaLymphoma
- Interventions
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 47
- Registration Number
- NCT00109031
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
- Conditions
- LeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2010-09-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00107354
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
- Conditions
- TeratomaExtragonadal Germ Cell TumorTesticular Germ Cell Tumor
- Interventions
- Biological: bleomycin sulfateDrug: cisplatinDrug: etoposideDrug: ifosfamideDrug: oxaliplatinDrug: paclitaxel
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 263
- Registration Number
- NCT00104676
- Locations
- 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇫🇷Centre Henri Becquerel, Rouen, France
🇸🇰National Cancer Institute - Bratislava, Bratislava, Slovakia
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
- Conditions
- Angioimmunoblastic T-cell LymphomaChildhood Burkitt LymphomaChildhood Immunoblastic Large Cell LymphomaHepatosplenic T-cell LymphomaIntraocular LymphomaNoncutaneous Extranodal LymphomaPeripheral T-cell LymphomaRecurrent Childhood Acute Lymphoblastic LeukemiaChildhood Nasal Type Extranodal NK/T-cell LymphomaRecurrent Childhood Anaplastic Large Cell Lymphoma
- Interventions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00101205
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Use of Topotecan in Patients With Refractory Acute Leukemia
- Conditions
- Non-Hodgkin's LymphomaLeukemia
- Interventions
- First Posted Date
- 2004-12-31
- Last Posted Date
- 2013-09-25
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 10
- Registration Number
- NCT00100477
- Locations
- 🇺🇸
North Florida/South Georgia Veterans Health System, Gainesville, Florida, United States
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: filgrastimBiological: rituximabDrug: cytarabineDrug: etoposideDrug: leucovorin calciumDrug: methotrexateDrug: temozolomide
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 47
- Registration Number
- NCT00098774
- Locations
- 🇺🇸
Saint Luke's Hospital - South, Overland Park, Kansas, United States
🇺🇸Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States
🇺🇸SUNY Upstate Medical University Hospital, Syracuse, New York, United States
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: L-asparaginaseDrug: doxorubicin hydrochlorideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateBiological: epratuzumabDrug: cytarabineDrug: prednisoneDrug: pegaspargaseDrug: dexrazoxane hydrochlorideDrug: methotrexateDrug: etoposideDrug: cyclophosphamideDrug: leucovorin calciumBiological: filgrastim
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 134
- Registration Number
- NCT00098839
- Locations
- 🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.